To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Phase 3CompletedNCT00150436

Pfizer276 enrolled

Overview

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

276

Conditions

Neuralgia

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia * Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks. Exclusion Criteria: * Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

Outcomes

Primary Outcomes

Safety Efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.